Bio-Techne (TECH) Stock Forecast, Price Target & Predictions
TECH Stock Forecast
Bio-Techne stock forecast is as follows: an average price target of $82.33 (represents a 9.38% upside from TECH’s last price of $75.27) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.
TECH Price Target
The average price target for Bio-Techne (TECH) is $82.33 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $84.00 to $80.00. This represents a potential 9.38% upside from TECH's last price of $75.27.
TECH Analyst Ratings
According to 7 Wall Street analysts, Bio-Techne's rating consensus is 'Buy'. The analyst rating breakdown for TECH stock is 0 'Strong Buy' (0.00%), 4 'Buy' (57.14%), 2 'Hold' (28.57%), 1 'Sell' (14.29%), and 0 'Strong Sell' (0.00%).
Bio-Techne Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 31, 2024 | Catherine Schulte | Robert W. Baird | $84.00 | $76.02 | 10.50% | 11.60% |
| Oct 30, 2024 | Paul Knight | KeyBanc | $80.00 | $76.02 | 5.24% | 6.28% |
| Aug 16, 2024 | Sung Ji Nam | Scotiabank | $83.00 | $74.19 | 11.87% | 10.27% |
| Dec 14, 2022 | Deutsche Bank | $100.00 | $86.98 | 14.97% | 32.86% | |
| Dec 12, 2022 | Citigroup | $100.00 | $80.73 | 23.87% | 32.86% | |
| Dec 07, 2022 | RBC Capital | $89.00 | $80.67 | 10.33% | 18.24% | |
| Dec 05, 2022 | Stephens | $105.00 | $82.44 | 27.37% | 39.50% | |
| May 05, 2022 | Paul Knight | KeyBanc | $125.00 | $98.96 | 26.31% | 66.07% |
| Apr 25, 2022 | Wells Fargo | $92.50 | $100.75 | -8.19% | 22.89% | |
| May 06, 2021 | Patrick B Donnelly | Citigroup | $106.25 | $102.45 | 3.71% | 41.16% |
The latest Bio-Techne stock forecast, released on Oct 31, 2024 by Catherine Schulte from Robert W. Baird, set a price target of $84.00, which represents a 10.50% increase from the stock price at the time of the forecast ($76.02), and a 11.60% increase from TECH last price ($75.27).
Bio-Techne Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 2 | 3 |
| Avg Price Target | - | $82.00 | $82.33 |
| Last Closing Price | $75.27 | $75.27 | $75.27 |
| Upside/Downside | -100.00% | 8.94% | 9.38% |
In the current month, the average price target of Bio-Techne stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Bio-Techne's last price of $75.27. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 30, 2024 | KeyBanc | Overweight | Overweight | Hold |
| Aug 16, 2024 | Scotiabank | Sector Outperform | Sector Outperform | Hold |
| Aug 13, 2024 | RBC Capital | Sector Perform | Sector Perform | Hold |
| May 22, 2024 | Deutsche Bank | Buy | Buy | Hold |
| May 22, 2024 | Citigroup | Buy | Neutral | Downgrade |
| May 02, 2024 | Scotiabank | Outperform | Outperform | Hold |
| Feb 02, 2024 | RBC Capital | Sector Perform | Sector Perform | Hold |
| Aug 28, 2023 | William Blair | Outperform | Initialise | |
| Dec 14, 2022 | Deutsche Bank | Buy | Initialise | |
| Dec 12, 2022 | Citigroup | Buy | Upgrade | |
| Dec 07, 2022 | RBC Capital | Sector Perform | Initialise | |
| Dec 05, 2022 | Stephens | Overweight | Overweight | Hold |
| Apr 25, 2022 | Wells Fargo | Underweight | Downgrade |
Bio-Techne's last stock rating was published by KeyBanc on Oct 30, 2024. The company gave TECH a "Overweight" rating, the same as its previous rate.
Bio-Techne Financial Forecast
Bio-Techne Revenue Forecast
| Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $272.60M | $276.94M | $301.32M | $294.15M | $271.58M | $269.65M | $288.23M | $290.38M | $269.28M | $257.72M | $259.03M | $243.55M | $224.25M | $204.20M | $175.83M | $194.68M |
| Avg Forecast | $400.43M | $383.42M | $347.75M | $345.50M | $359.12M | $346.71M | $312.99M | $312.98M | $328.78M | $318.23M | $286.14M | $280.22M | $306.49M | $292.15M | $277.55M | $287.66M | $307.22M | $296.61M | $288.80M | $281.83M | $286.71M | $279.27M | $266.44M | $252.78M | $244.65M | $228.22M | $206.50M | $185.03M | $163.91M | $185.93M |
| High Forecast | $405.90M | $388.65M | $352.50M | $350.22M | $364.02M | $351.44M | $317.26M | $317.25M | $333.27M | $320.18M | $288.39M | $281.67M | $306.49M | $292.25M | $285.67M | $292.69M | $311.41M | $300.66M | $292.74M | $281.83M | $286.71M | $279.27M | $266.44M | $252.78M | $244.65M | $228.22M | $206.50M | $185.03M | $163.91M | $185.93M |
| Low Forecast | $395.90M | $379.08M | $343.82M | $341.60M | $355.06M | $342.79M | $309.45M | $309.44M | $325.06M | $316.84M | $283.30M | $278.77M | $306.49M | $292.05M | $271.57M | $282.89M | $303.75M | $293.26M | $285.53M | $281.83M | $286.71M | $279.27M | $266.44M | $252.78M | $244.65M | $228.22M | $206.50M | $185.03M | $163.91M | $185.93M |
| # Analysts | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 8 | 8 | 4 | 4 | 4 | 5 | 11 | 5 | 9 | 5 | 4 | 4 | 7 | 5 | 5 | 10 | 7 | 5 | 7 | 7 | 9 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.98% | 0.96% | 0.98% | 0.99% | 0.94% | 0.96% | 1.01% | 1.04% | 1.01% | 1.02% | 1.06% | 1.07% | 1.09% | 1.10% | 1.07% | 1.05% |
Bio-Techne's average Quarter revenue forecast for Mar 24 based on 4 analysts is $292.15M, with a low forecast of $292.05M, and a high forecast of $292.25M. TECH's average Quarter revenue forecast represents a 7.17% increase compared to the company's last Quarter revenue of $272.60M (Dec 23).
Bio-Techne EBITDA Forecast
| Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 8 | 8 | 4 | 4 | 4 | 5 | 11 | 5 | 9 | 5 | 4 | 4 | 7 | 5 | 5 | 10 | 7 | 5 | 7 | 7 | 9 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $38.00M | $84.40M | $121.45M | $107.18M | $94.59M | $82.96M | $106.44M | $115.81M | $122.30M | $96.16M | $35.39M | $69.50M | $80.97M | $64.84M | $87.13M | $72.42M |
| Avg Forecast | $147.10M | $140.85M | $127.75M | $126.92M | $131.92M | $127.36M | $114.98M | $114.97M | $120.78M | $116.90M | $105.11M | $102.94M | $112.59M | $100.87M | $101.96M | $105.67M | $112.86M | $91.70M | $127.76M | $84.53M | $86.00M | $83.37M | $79.92M | $75.82M | $73.38M | $58.74M | $61.94M | $55.50M | $49.16M | $57.30M |
| High Forecast | $149.10M | $142.77M | $129.49M | $128.65M | $133.72M | $129.10M | $116.55M | $116.54M | $122.43M | $117.62M | $105.94M | $103.47M | $112.59M | $121.05M | $104.94M | $107.52M | $114.40M | $110.04M | $153.32M | $84.53M | $86.00M | $100.04M | $79.92M | $75.82M | $73.38M | $70.48M | $61.94M | $55.50M | $49.16M | $68.76M |
| Low Forecast | $145.43M | $139.26M | $126.30M | $125.48M | $130.43M | $125.92M | $113.68M | $113.67M | $119.41M | $116.39M | $104.07M | $102.41M | $112.59M | $80.70M | $99.76M | $103.92M | $111.58M | $73.36M | $102.21M | $84.53M | $86.00M | $66.69M | $79.92M | $75.82M | $73.38M | $46.99M | $61.94M | $55.50M | $49.16M | $45.84M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.37% | 0.80% | 1.08% | 1.17% | 0.74% | 0.98% | 1.24% | 1.39% | 1.53% | 1.27% | 0.48% | 1.18% | 1.31% | 1.17% | 1.77% | 1.26% |
4 analysts predict TECH's average Quarter EBITDA for Mar 24 to be $100.87M, with a high of $121.05M and a low of $80.70M. This is 165.43% upper than Bio-Techne's previous annual EBITDA (Dec 23) of $38.00M.
Bio-Techne Net Income Forecast
| Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 8 | 8 | 4 | 4 | 4 | 5 | 11 | 5 | 9 | 5 | 4 | 4 | 7 | 5 | 5 | 10 | 7 | 5 | 7 | 7 | 9 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $27.46M | $50.99M | $75.48M | $70.22M | $50.01M | $89.56M | $61.52M | $60.74M | $72.06M | $69.61M | $14.96M | $45.78M | $46.27M | $33.40M | $58.84M | $36.43M |
| Avg Forecast | $113.51M | $103.61M | $84.46M | $84.98M | $100.86M | $94.88M | $74.72M | $75.94M | $89.28M | $83.06M | $62.30M | $61.49M | $79.74M | $64.67M | $66.41M | $70.03M | $88.05M | $58.80M | $83.76M | $73.52M | $83.39M | $53.45M | $71.88M | $69.15M | $68.33M | $38.69M | $55.03M | $44.37M | $30.23M | $28.83M |
| High Forecast | $115.52M | $105.45M | $85.95M | $86.49M | $102.65M | $96.56M | $76.05M | $77.29M | $90.86M | $84.53M | $65.58M | $62.16M | $79.74M | $77.61M | $71.15M | $76.40M | $89.61M | $70.55M | $100.51M | $73.52M | $83.39M | $64.14M | $71.88M | $69.15M | $68.33M | $46.43M | $55.03M | $44.37M | $30.23M | $34.59M |
| Low Forecast | $111.84M | $102.09M | $83.21M | $83.73M | $99.38M | $93.49M | $73.62M | $74.83M | $87.97M | $81.46M | $60.66M | $60.82M | $79.73M | $51.74M | $61.67M | $65.26M | $86.76M | $47.04M | $67.00M | $73.52M | $83.39M | $42.76M | $71.88M | $69.15M | $68.33M | $30.95M | $55.03M | $44.37M | $30.23M | $23.06M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.41% | 0.73% | 0.86% | 1.19% | 0.60% | 1.22% | 0.74% | 1.14% | 1.00% | 1.01% | 0.22% | 1.18% | 0.84% | 0.75% | 1.95% | 1.26% |
Bio-Techne's average Quarter net income forecast for Mar 24 is $64.67M, with a range of $51.74M to $77.61M. TECH's average Quarter net income forecast represents a 135.48% increase compared to the company's last Quarter net income of $27.46M (Dec 23).
Bio-Techne SG&A Forecast
| Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 8 | 8 | 4 | 4 | 4 | 5 | 11 | 5 | 9 | 5 | 4 | 4 | 7 | 5 | 5 | 10 | 7 | 5 | 7 | 7 | 9 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $115.67M | $105.33M | $86.75M | $99.24M | $93.01M | $99.38M | $96.63M | $89.27M | $100.69M | $86.17M | $51.61M | $82.60M | $83.12M | $72.60M | $65.80M | $66.32M |
| Avg Forecast | $137.28M | $131.45M | $119.22M | $118.45M | $123.12M | $118.87M | $107.31M | $107.30M | $112.72M | $109.10M | $98.10M | $96.07M | $105.08M | $95.05M | $95.15M | $98.62M | $105.33M | $86.41M | $105.19M | $97.91M | $99.61M | $78.56M | $92.57M | $87.82M | $85.00M | $69.81M | $71.74M | $64.28M | $56.95M | $52.48M |
| High Forecast | $139.16M | $133.24M | $120.85M | $120.07M | $124.80M | $120.49M | $108.77M | $108.76M | $114.26M | $109.77M | $98.87M | $96.57M | $105.08M | $114.06M | $97.94M | $100.35M | $106.76M | $103.69M | $126.23M | $97.91M | $99.61M | $94.27M | $92.57M | $87.82M | $85.00M | $83.77M | $71.74M | $64.28M | $56.95M | $62.97M |
| Low Forecast | $135.73M | $129.96M | $117.87M | $117.11M | $121.73M | $117.52M | $106.09M | $106.09M | $111.44M | $108.62M | $97.12M | $95.57M | $105.08M | $76.04M | $93.10M | $96.99M | $104.14M | $69.13M | $84.15M | $97.91M | $99.61M | $62.85M | $92.57M | $87.82M | $85.00M | $55.85M | $71.74M | $64.28M | $56.95M | $41.98M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.22% | 1.07% | 0.82% | 1.15% | 0.88% | 1.01% | 0.97% | 1.14% | 1.09% | 0.98% | 0.61% | 1.18% | 1.16% | 1.13% | 1.16% | 1.26% |
Bio-Techne's average Quarter SG&A projection for Mar 24 is $95.05M, based on 4 Wall Street analysts, with a range of $76.04M to $114.06M. The forecast indicates a -17.82% fall compared to TECH last annual SG&A of $115.67M (Dec 23).
Bio-Techne EPS Forecast
| Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 8 | 8 | 4 | 4 | 4 | 5 | 11 | 5 | 9 | 5 | 4 | 4 | 7 | 5 | 5 | 10 | 7 | 5 | 7 | 7 | 9 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $0.17 | $0.32 | $0.48 | $0.45 | $0.32 | $0.57 | $0.39 | $0.39 | $0.46 | $0.42 | $0.09 | $0.28 | $0.29 | $0.21 | $0.37 | $0.23 |
| Avg Forecast | $0.70 | $0.64 | $0.52 | $0.53 | $0.63 | $0.59 | $0.46 | $0.47 | $0.55 | $0.52 | $0.39 | $0.38 | $0.49 | $0.45 | $0.41 | $0.43 | $0.55 | $0.53 | $0.49 | $0.46 | $0.52 | $0.50 | $0.45 | $0.43 | $0.43 | $0.39 | $0.34 | $0.28 | $0.19 | $0.29 |
| High Forecast | $0.72 | $0.65 | $0.53 | $0.54 | $0.64 | $0.60 | $0.47 | $0.48 | $0.56 | $0.52 | $0.41 | $0.39 | $0.49 | $0.45 | $0.44 | $0.47 | $0.56 | $0.54 | $0.50 | $0.46 | $0.52 | $0.50 | $0.45 | $0.43 | $0.43 | $0.39 | $0.34 | $0.28 | $0.19 | $0.29 |
| Low Forecast | $0.69 | $0.63 | $0.52 | $0.52 | $0.62 | $0.58 | $0.46 | $0.46 | $0.55 | $0.51 | $0.38 | $0.38 | $0.49 | $0.45 | $0.38 | $0.41 | $0.54 | $0.52 | $0.48 | $0.46 | $0.52 | $0.50 | $0.45 | $0.43 | $0.43 | $0.39 | $0.34 | $0.28 | $0.19 | $0.29 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.41% | 0.74% | 0.88% | 0.85% | 0.66% | 1.25% | 0.75% | 0.78% | 1.03% | 0.98% | 0.21% | 0.73% | 0.84% | 0.76% | 1.97% | 0.80% |
According to 4 Wall Street analysts, Bio-Techne's projected average Quarter EPS for Mar 24 is $0.45, with a low estimate of $0.45 and a high estimate of $0.45. This represents a 166.34% increase compared to TECH previous annual EPS of $0.17 (Dec 23).
Bio-Techne Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| VTYX | Ventyx Biosciences | $2.37 | $33.86 | 1328.69% | Buy |
| LEGN | Legend Biotech | $34.68 | $89.60 | 158.36% | Buy |
| APLS | Apellis Pharmaceuticals | $34.53 | $70.80 | 105.04% | Buy |
| LQDA | Liquidia | $11.31 | $22.33 | 97.44% | Buy |
| PCVX | Vaxcyte | $89.86 | $148.80 | 65.59% | Buy |
| AKRO | Akero Therapeutics | $30.61 | $50.00 | 63.35% | Buy |
| REPL | Replimune Group | $11.72 | $19.00 | 62.12% | Buy |
| ASND | Ascendis Pharma | $140.30 | $211.14 | 50.49% | Buy |
| BGNE | BeiGene | $179.06 | $267.33 | 49.30% | Buy |
| BMRN | BioMarin Pharmaceutical | $67.19 | $94.43 | 40.54% | Buy |
| NUVL | Nuvalent | $88.10 | $114.80 | 30.31% | Buy |
| BPMC | Blueprint Medicines | $96.48 | $122.60 | 27.07% | Buy |
| TVTX | Travere Therapeutics | $17.14 | $21.75 | 26.90% | Buy |
| ALNY | Alnylam Pharmaceuticals | $246.58 | $310.60 | 25.96% | Buy |
| UTHR | United Therapeutics | $379.69 | $440.40 | 15.99% | Buy |
| TECH | Bio-Techne | $75.27 | $82.33 | 9.38% | Buy |
| HALO | Halozyme Therapeutics | $48.60 | $52.00 | 7.00% | Buy |
| EXEL | Exelixis | $34.69 | $30.89 | -10.95% | Buy |